Pharmacokinetics of First-Line Drugs Among Children With Tuberculosis in Rural Tanzania

Journal of the Pediatric Infectious Diseases Society - Tập 9 Số 1 - Trang 14-20 - 2020
Museveni Justine1, Anita Yeconia1, Ingi Nicodemu1, Domitila Augustino1, Jean Gratz1,2, Estomih Mduma1, Scott K. Heysell2, Sokoine Kivuyo3, Sayoki Mfinanga3, Charles A. Peloquin4, Theodore Zagurski4, Gibson Kibiki5, Blandina T. Mmbaga6, Eric R. Houpt2, Tania A. Thomas2
1Center for Global Health Research, Haydom Lutheran Hospital, Haydom, Tanzania
2Division of Infectious Diseases and International Health, University of Virginia, Charlottesville
3National Institute of Medical Research Muhimbili, Dar es Salaam, Tanzania
4Infectious Disease Pharmacokinetic Laboratory, University of Florida, Gainesville
5East African Health Research Commission, East African Community, Arusha, Tanzania
6Kilimanjaro Clinical Research Institute, Kilimanjaro Christian Medical College, Moshi, Tanzania

Tóm tắt

AbstractBackgroundDosing recommendations for treating childhood tuberculosis (TB) were revised by the World Health Organization, yet so far, pharmacokinetic studies that have evaluated these changes are relatively limited. We evaluated plasma drug concentrations of rifampicin (RIF), isoniazid (INH), pyrazinamide (PZA), and ethambutol (EMB) among children undergoing TB treatment in Tanzania when these dosing recommendations were being implemented.MethodsAt the end of intensive-phase TB therapy, blood was obtained 2 hours after witnessed medication administration to estimate the peak drug concentration (C2h), measured using high-performance liquid chromatography or liquid chromatography–tandem mass spectrometry methods. Differences in median drug concentrations were compared on the basis of the weight-based dosing strategy using the Mann–Whitney U test. Risk factors for low drug concentrations were analyzed using multivariate regression analysis.ResultsWe enrolled 51 human immunodeficiency virus–negative children (median age, 5.3 years [range, 0.75–14 years]). The median C2hs were below the target range for each TB drug studied. Compared with children who received the “old” dosages, those who received the “revised” WHO dosages had a higher median C2h for RIF (P = .049) and PZA (P = .015) but not for INH (P = .624) or EMB (P = .143); however, these revised dosages did not result in the target range for RIF, INH, and EMB being achieved. A low starting dose was associated with a low C2h for RIF (P = .005) and PZA (P = .005). Malnutrition was associated with a low C2h for RIF (P = .001) and INH (P = .001).ConclusionsAmong this cohort of human immunodeficiency virus–negative Tanzanian children, use of the revised dosing strategy for treating childhood TB did not result in the target drug concentration for RIF, INH, or EMB being reached.

Từ khóa


Tài liệu tham khảo

World Health Organization, 2017, Global tuberculosis report 2017. WHO/HTM/TB/201723, 262

World Health Organization, 2013, Roadmap for childhood tuberculosis: towards zero deaths

World Health Organization, 2014, Guidance for national tuberculosis programmes on the management of tuberculosis in children, 2nd ed

Graham, 2011, Treatment of paediatric TB: revised WHO guidelines, Paediatr Respir Rev, 12, 22, 10.1016/j.prrv.2010.09.005

Alsultan, 2014, Therapeutic drug monitoring in the treatment of tuberculosis: an update, Drugs, 74, 839, 10.1007/s40265-014-0222-8

Batchelor, 2015, Paediatric pharmacokinetics: key considerations, Br J Clin Pharmacol, 79, 395, 10.1111/bcp.12267

Donald, 2006, Ethambutol dosage for the treatment of children: literature review and recommendations, Int J Tuberc Lung Dis, 10, 1318

Abdel-Rahman

World Health Organization, 2010, Rapid advice: treatment of tuberculosis in children, 19

Thee, 2011, Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations, Antimicrob Agents Chemother, 55, 5560, 10.1128/AAC.05429-11

National Tuberculosis and Leprosy Programme, 2012, National Guidelines for the Management of Tuberculosis in Children, 1st ed

Kwara, 2016, Pharmacokinetics of first-line antituberculosis drugs using WHO revised dosage in children with tuberculosis with and without HIV coinfection, J Pediatric Infect Dis Soc, 5, 356, 10.1093/jpids/piv035

Antwi, 2017, Pharmacokinetics of the first-line antituberculosis drugs in Ghanaian children with tuberculosis with or without HIV coinfection, Antimicrob Agents Chemother, 61, e01701-16, 10.1128/AAC.01701-16

Hiruy, 2015, Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study, J Antimicrob Chemother, 70, 1115, 10.1093/jac/dku478

McIlleron, 2016, Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes, Int J Tuberc Lung Dis, 20, 915, 10.5588/ijtld.15.0833

Bekker, 2016, Pharmacokinetics of rifampin, isoniazid, pyrazinamide, and ethambutol in infants dosed according to revised WHO-recommended treatment guidelines, Antimicrob Agents Chemother, 60, 2171, 10.1128/AAC.02600-15

Verhagen, 2010, Human immunodeficiency virus and tuberculosis coinfection in children: challenges in diagnosis and treatment, Pediatr Infect Dis J, 29, e63, 10.1097/INF.0b013e3181ee23ae

Panchagnula, 2004, Biopharmaceutic and pharmacokinetic aspects of variable bioavailability of rifampicin, Int J Pharm, 271, 1, 10.1016/j.ijpharm.2003.11.031

Yang, 2018, Evaluation of the adequacy of the 2010 Revised World Health Organization recommended dosages of the first-line antituberculosis drugs for children: adequacy of revised dosages of TB drugs for children, Pediatr Infect Dis J, 37, 43, 10.1097/INF.0000000000001687

Mduma, 2014, The etiology, risk factors, and interactions of enteric infections and malnutrition and the consequences for child health and development study (MAL-ED): description of the Tanzanian site, Clin Infect Dis, 59, S325, 10.1093/cid/ciu439

Jaganath, 2012, Childhood tuberculosis and malnutrition, J Infect Dis, 206, 1809, 10.1093/infdis/jis608

Kumar, 2014, Co-morbidities in hospitalized children with severe acute malnutrition, Indian Pediatr, 51, 125, 10.1007/s13312-014-0343-x

Oshikoya, 2009, Pathophysiological changes that affect drug disposition in protein-energy malnourished children, Nutr Metab (Lond), 6, 50, 10.1186/1743-7075-6-50

Ramachandran, 2011, Pharmacokinetics of anti-tuberculosis drugs in children, Indian J Pediatr, 78, 435, 10.1007/s12098-010-0304-x

Pinheiro, 2006, Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis, Braz J Infect Dis, 10, 374, 10.1590/S1413-86702006000600003

Owino, 2016, Environmental enteric dysfunction and growth failure/stunting in global child health, Pediatrics, 138, pii:e20160641, 10.1542/peds.2016-0641

Schaaf, 2009, Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis, BMC Med, 7, 19, 10.1186/1741-7015-7-19

Mukherjee, 2015, Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in Indian children, BMC Infect Dis, 15, 126, 10.1186/s12879-015-0862-7

Roy, 2010, Pharmacokinetics of isoniazid in moderately malnourished children with tuberculosis, Int J Tuberc Lung Dis, 14, 374

McIlleron, 2009, Isoniazid plasma concentrations in a cohort of South African children with tuberculosis: implications for international pediatric dosing guidelines, Clin Infect Dis, 48, 1547, 10.1086/598192

Ramachandran, 2015, Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India, Antimicrob Agents Chemother, 59, 1162, 10.1128/AAC.04338-14

Ramachandran, 2013, Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children, Int J Tuberc Lung Dis, 17, 800, 10.5588/ijtld.12.0628

McIlleron, 2011, Pyrazinamide plasma concentrations in young children with tuberculosis, Pediatr Infect Dis J, 30, 262, 10.1097/INF.0b013e3181fbefe1

Chideya, 2009, Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana, Clin Infect Dis, 48, 1685, 10.1086/599040

Ramachandran, 2016, Low serum concentrations of rifampicin and pyrazinamide associated with poor treatment outcomes in children with tuberculosis related to HIV status, Pediatr Infect Dis J, 35, 530, 10.1097/INF.0000000000001069

Schaaf, 2005, Isoniazid pharmacokinetics in children treated for respiratory tuberculosis, Arch Dis Child, 90, 614, 10.1136/adc.2004.052175

Dayal, 2018, Pharmacokinetic study of isoniazid and pyrazinamide in children: impact of age and nutritional status, Arch Dis Child, 10.1136/archdischild-2017-313910

Boeree, 2015, A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis, Am J Respir Crit Care Med, 191, 1058, 10.1164/rccm.201407-1264OC

Boeree, 2017, High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial, Lancet Infect Dis, 17, 39, 10.1016/S1473-3099(16)30274-2

Thông tin
Thông tin xuất bản

Journal of the Pediatric Infectious Diseases Society

Tập 9 Số 1

14-20

Thông tin tác giả